Fluocinonide

Inflammation, Dermatosis, Itching

Treatment

5 FDA approvals

20 Active Studies for Fluocinonide

What is Fluocinonide

Fluocinonide

The Generic name of this drug

Treatment Summary

A topical steroid used to reduce inflammation and treat eczema.

Fluocinonide

is the brand name

image of different drug pills on a surface

Fluocinonide Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Fluocinonide

Fluocinonide

1984

147

Approved as Treatment by the FDA

Fluocinonide, otherwise known as Fluocinonide, is approved by the FDA for 5 uses like Inflammation and Itching .

Inflammation

Used to treat Inflammation in combination with Gramicidin D

Itching

Used to treat Pruritus in combination with Gramicidin D

Inflammation

Used to treat Inflammation in combination with Gramicidin D

Pruritus

Used to treat Pruritus in combination with Gramicidin D

Dermatosis

Used to treat Dermatosis in combination with Gramicidin D

Effectiveness

How Fluocinonide Affects Patients

Fluocinonide is a strong medicine used to reduce inflammation and treat skin conditions like eczema. It helps reduce itching, redness, dryness, crusting, scaling, inflammation, and other discomforts caused by skin inflammation.

How Fluocinonide works in the body

Fluocinonide is a steroid used to reduce inflammation in the skin. It binds to a receptor in the cell nucleus and causes changes in gene expression. Fluocinonide works by blocking the production of substances called prostaglandins and leukotrienes, which are responsible for inflammation. It also blocks the action of certain proteins that help cells stick together and move around. The steroid also weakens the immune system by reducing lymphocytes and other immune system components. Finally, it interferes with the body's ability to create and use energy, leading to increased glucose levels in the blood.

When to interrupt dosage

The prescribed dosage of Fluocinonide is contingent upon the determined condition, including Inflammation, Dermatosis and Itch. The amount of dosage likewise varies, in accordance with the technique of delivery (e.g. Topical or Jelly - Topical) featured in the table beneath.

Condition

Dosage

Administration

Inflammation

, 0.0005 mg/mg, 0.5 mg/mL, 0.001 mg/mg, 0.05 %, 0.01 %, 0.00005 mg/mg

, Gel, Gel - Topical, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Solution - Topical, Solution, Jelly, Jelly - Topical, Cream; Emulsion, Cream; Emulsion - Topical, Kit, Kit - Topical

Dermatosis

, 0.0005 mg/mg, 0.5 mg/mL, 0.001 mg/mg, 0.05 %, 0.01 %, 0.00005 mg/mg

, Gel, Gel - Topical, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Solution - Topical, Solution, Jelly, Jelly - Topical, Cream; Emulsion, Cream; Emulsion - Topical, Kit, Kit - Topical

Itching

, 0.0005 mg/mg, 0.5 mg/mL, 0.001 mg/mg, 0.05 %, 0.01 %, 0.00005 mg/mg

, Gel, Gel - Topical, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Solution - Topical, Solution, Jelly, Jelly - Topical, Cream; Emulsion, Cream; Emulsion - Topical, Kit, Kit - Topical

Warnings

There are 20 known major drug interactions with Fluocinonide.

Common Fluocinonide Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Fluocinonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Fluocinonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Fluocinonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Fluocinonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Fluocinonide is combined with Abetimus.

Fluocinonide Toxicity & Overdose Risk

Possible side effects of using this drug include acne, burning sensation, dry skin, increased hair growth, skin infections, irritation, itching, discoloration, heat rash, inflammation, skin thinning or softening, and stretch marks.

image of a doctor in a lab doing drug, clinical research

Fluocinonide Novel Uses: Which Conditions Have a Clinical Trial Featuring Fluocinonide?

Currently, 200 active clinical trials are assessing the potential of Fluocinonide to alleviate Itch, Inflammation and Dermatosis.

Condition

Clinical Trials

Trial Phases

Dermatosis

0 Actively Recruiting

Inflammation

58 Actively Recruiting

Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Fluocinonide Reviews: What are patients saying about Fluocinonide?

5

Patient Review

6/24/2017

Fluocinonide for Psoriasis of Scalp

This solution is essential to my life. I have scalp psoriasis and it's the only thing that works for me. It might burn at first, but soon enough you'll start noticing a difference.

5

Patient Review

10/24/2017

Fluocinonide for Skin Condition

This cream quickly and effectively relieved both my chigger bites and the rash that developed from sweating and friction.

5

Patient Review

2/5/2021

Fluocinonide for Skin Condition

This ointment, prescribed by my podiatrist has done an excellent job of clearing up my foot fungus. However, it hasn't cured the problem entirely. I'm also not a fan of ointments in general, so that's why it only gets four stars from me.

5

Patient Review

3/27/2019

Fluocinonide for Itching

I've been using this for years with great success. Whenever I have an area of severe itching, I apply a thin film and the sensation subsides within hours - it never returns!

5

Patient Review

5/15/2016

Fluocinonide for Atopic Dermatitis

This medication has been working wonders for my eczema. It cleared up the rash within just a couple of days, and if I start to feel an itch coming on, I can apply it and prevent the redness and blisters from even forming. I'm really amazed at how well this medication works!

4

Patient Review

5/2/2017

Fluocinonide for Atopic Dermatitis

While this medication did clear the redness, I found myself feeling really down and depressed. This was strange and surprising to me, so I wanted to warn others in case this could be a more serious side effect for someone with an underlying condition.

2.7

Patient Review

12/10/2017

Fluocinonide for Psoriasis of Scalp

It's hard to use this treatment by yourself, but it did clear up my scalp psoriasis. However, the symptoms came back after I stopped using it for a week. Another downside is that I experienced a lot of hair loss.

2.7

Patient Review

8/23/2021

Fluocinonide for Itching

I didn't see any reduction in itchiness when using this cream, unfortunately.

2.3

Patient Review

3/30/2018

Fluocinonide for Rash

I was admitted to the hospital for cellulitis on my arm and then started breaking out with an itchy rash. I have been to four different doctors, and one prescribed medication for a fungus under my nails which I didn't have. I am hoping that this cream will work because the itch is driving me insane. It's spreading from my armpits to my chest, between my legs, and up my neck. The instructions say not to use it on your armpits, but it seems to be worse in areas that are moist. If anyone has any advice, please let me know.

2.3

Patient Review

3/22/2019

Fluocinonide for Itching

I was really hoping this would help me more than it did. It's not that it didn't work at all, but I still have a long way to go before finding something that completely eliminates my itchiness.

1

Patient Review

8/22/2017

Fluocinonide for Skin Rash that Becomes Thick & Discolored From Rubbing It

I started taking this medication and - while it did stop the severe itching I was experiencing from eczema - it caused huge, pus-filled bumps that were incredibly inflamed. My face also broke out in terrible acne. Needless to say, I stopped taking this medication.

1

Patient Review

1/6/2021

Fluocinonide for Skin Condition

The 0.01% concentration didn't help me at all. I'm wondering if a stronger dose would've made a difference.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fluocinonide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is fluocinonide cream an antifungal?

"No, fluocinonide (Vanos) is not an antifungal medication. It is a corticosteroid. Depending on your personal skin condition, you might be prescribed fluocinonide (Vanos) and an antifungal at the same time."

Answered by AI

What are side effects of fluocinonide?

"Possible side effects of the medication include: painful and/or itchy skin, soreness, redness and scaling around the mouth, and severe burning, crusting, or flaking of the skin."

Answered by AI

What is fluocinonide used to treat?

"Fluocinonide is a topical cream used to treat various skin conditions including psoriasis, eczema, and discomfort. The cream works by reducing inflammation and itchy, dry skin."

Answered by AI

Is fluocinonide a strong steroid?

"Fluocinonide is a medication used to reduce swelling, itching, and redness in conditions such as eczema and psoriasis. It is a strong corticosteroid."

Answered by AI

Clinical Trials for Fluocinonide

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions we aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, we may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Fluocinonide clinical trials?

We made a collection of clinical trials featuring Fluocinonide, we think they might fit your search criteria.
Go to Trials
Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT

The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)

Waitlist Available
Has No Placebo

UConn Health

Cutter Lindbergh, Ph.D.

Image of Department of Nutritional Sciences in Storrs, United States.

Freeze-dried Grape Powder for Healthy Aging

50 - 75
All Sexes
Storrs, CT

The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults. The main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant/grape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.

Recruiting
Paid Trial

Department of Nutritional Sciences

Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Phase 2
Recruiting

Abcentra Investigational Site (+6 Sites)

Abcentra

Image of School of Public Health in Bloomington, United States.

High Salt Intake for High Blood Pressure

60 - 85
All Sexes
Bloomington, IN

Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.

Recruiting
Has No Placebo

School of Public Health

Have you considered Fluocinonide clinical trials?

We made a collection of clinical trials featuring Fluocinonide, we think they might fit your search criteria.
Go to Trials
Image of Goldring Center for High Performance Sport in Toronto, Canada.

Physical Activity for Delayed Onset Muscle Soreness

18 - 35
All Sexes
Toronto, Canada

After completing novel activity or exercise we may experience exercise-induced muscle damage (EIMD), resulting in a period of reduced muscle function and delayed onset muscle soreness (DOMS). DOMS is characterized by muscle pain and tenderness that typically resolves within a week. While the precise cause of DOMS is unknown, there is growing evidence implicating damage to the connective tissue that surrounds our muscle fibers and is related to a small amount of inflammation. This inflammation is a normal part of our body's ability to recovery from injuries and may be visualized through the use of ultrasound technology. A variety of recovery techniques have been proposed that may help with the recovery of DOMS such as massage and electrical muscle stimulation, but these are not always accessible. Therefore, we are interested in investigating whether the number of daily steps can affect how you experience DOMS.

Waitlist Available
Has No Placebo

Goldring Center for High Performance Sport

Image of UCSF in San Francisco, United States.

Moisturizers for Aging

65+
All Sexes
San Francisco, CA

This is a randomized, investigator-blinded, self-controlled pilot study of the physiologic response to topical moisturizers among older adults with dry skin. The overarching hypothesis is that skin barrier decline is an important source of chronic inflammation, and that skin barrier restoration with moisturizers can reduce serum biomarkers of inflammation. The primary objective is to determine the feasibility for a larger trial, and the secondary objectives are to determine the extent to which measures of serum inflammation, skin barrier function, and the skin microbiome change in response to moisturizers. Participants will be asked to apply one of two topical moisturizers that are widely available over the counter in the US (Vaseline® 100% pure petroleum jelly or CeraVe® moisturizing cream) once daily for 4 weeks to the front of the torso, buttocks, arms, and legs. Subjects will act as their own control (i.e. they will be asked to apply the study moisturizer they are randomized to for one intervention period (4 weeks) and not to apply topical moisturizers for the other 4- week intervention period). Participants will be randomized in a 1:1:1:1 ratio to one of 4 treatment groups: i. no intervention then CeraVe; ii. CeraVe then no intervention; iii. no intervention then Vaseline; iv. Vaseline then no intervention. At each visit (baseline, week 4, and week 8), participants will undergo skin barrier testing, skin microbiome sampling, and phlebotomy to measure serum inflammatory markers.

Phase 4
Recruiting

UCSF

Katrina Abuabara, MD

Have you considered Fluocinonide clinical trials?

We made a collection of clinical trials featuring Fluocinonide, we think they might fit your search criteria.
Go to Trials